VE416 for Treatment of Food Allergy

Phase 1/2 Recruiting 60 enrolled Massachusetts General Hospital Vedanta Biosciences, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone.

Timeline

Start: 2019-06-28
Primary completion: 2023-11-01
Completion: 2024-01-01

Publications

Berin MC. Dysbiosis in food allergy and implications for microbial therapeutics. J Clin Invest. 2021 Jan 19;131(2):e144994. doi: 10.1172/JCI144994.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VE416	Other / unclassified	—	Oral
Subject	Vancomycin	Other / unclassified	—	Oral

VE416 for Treatment of Food Allergy

Summary

Timeline

Publications

Drugs

Indications